TechnoPhage currently holds a well-balanced and diversified product portfolio addressing key therapeutic areas while simultaneously being agile in meeting the challenges of the rapidly evolving pharmaceutical industry.
TechnoPhage’s strategy is based on developing new therapeutics from early discovery to clinical development, including in-house capacity for process development and GMP production.
TechnoPhage is seeking further investment and partnerships to take its products from preclinical to clinical development.
Our track record
TechnoPhage has key partnerships with leading players in both National and International pharmaceutical industry. Under partnering agreements, TechnoPhage has taken several products into pre-clinical testing and one to clinical trials.
Technophage launched in 2019 Vision AB a spin-off company dedicated to developing small domain antibody (SdAb) targeting ophthalmology indications. More news soon to come!
VectorB2B (www.vectorb2b.com) is a private association formed in January 2019 between Portuguese private and public partners, including Technophage. The aim is to gather the scattered capacities of the academic and industrial shareholders in the sector of health biotechnology and transform these into viable economical assets, by providing integrated services in drug discovery and screening, project design and implementation, contract research and contract manufacturing.